Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
AChE inhibitor
Donepezil is a centrally acting reversible acetylcholinesterase inhibitor. -
AChE inhibitor
Galanthamine is an AChE inhibitor with IC50 of 14 nM. -
AChE inhibitor
Neostigmine bromide is a reversible acetylcholine esterase inhibitor that binds to the anionic binding site of AChE. -
AChE inhibitor
Rivastigmine tartrate is a dual cholinesterase inhibitor (ChEI). It inhibits both butyrylcholinesterase (BChE) and acetylcholinesterase (AChE). -
AChE inhibitor
Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM. -
AChE inhibitor
Desoxypeganine hydrochloride is an AChE (acetylcholinesterase) inhibitor that has been used in the treatment of Alzheimer's dementia. -
AChE and BChE inhibitor
Rivastigmine, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesterase. -
AChE inhibitor
Acotiamide is a drug approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia. -
AChE and BChE inhibitor
Tacrine hydrochloride hydrate is an inhibitor of both acetyl (AChE) and butyryl-cholinestrase (BChE) with IC50s of 31 nM and 25.6 nM, respectively. -
acetylcholinesterase inhibitor
Pitofenone hydrochloride is an antispasmodic agent. It acts as a potent inhibitor of acetylcholinesterase activity. -
AChE & butyrylcholinesterase inhibitor
Tacrine is a derivative of aminoacridine that functions as an inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (IC50s = 31 and 26.5 nM, respectively). -
BChE inhibitor
Drofenine hydrochloride is a potent competitive inhibitor of BChE, and the ki values of Drofenine is calculated to be 3 uM. -
acetylcholinesterase inhibitor
Edrophonium Chloride, also known as Tensilon, is an acetylcholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. Edrophonium Chloride has also been used as an antidote to curare principles. -
BuChE inhibitor
BuChE-IN-TM-10 (TM-10) is a potent butyrylcholinesterase (BuChE) inhibitor, with an IC50 of 8.9 nM. -
AChE inhibitor
Acetyllovastatin, a acetate of Lovastatin, presentes a moderate inhibitory effect against the enzyme acetylcholinesterase with an IC50 of 79 μg/mL. Lovastatin has been found to display antifungal activity, and suppresses proliferation of a number of transformed cell lines. -
cholinesterase noncompetitive inhibitor
(+)-Phenserine is a novel selective cholinesterase noncompetitive inhibitor with an IC50 of 45.3 μM. -
AChE inhibitor
(±)-Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD). -
cholinesterase inhibitor
(R)-Rivastigmine D6 (tartrate) is the deuterium labeled (R)-Rivastigmine, which is an cholinesterase inhibitor. -
Inhibitor of U46619-induced Rat Platelet Aggregation
Timosaponin AIII is a potent Inhibitor of U46619-induced Rat Platelet Aggregation, Selectively Inhibiting TxA2-induced Platelet Activation, Preferably Suppressing TP-mediated Activation of Gq, not G12/13, Signaling Pathways. -
AChE inhibitor
Distigmine Bromide, also known as Ubretid and BC-51, is an acetylcholinesterase inhibitor used for the treatment of underactive neurogenic bladder and myasthenia gravis. -
AChE inhibitor
Picfeltarraenin IA is a triterpenoid compound isolated from *Picria fel-terrae* (*P. fel-terrae*) that functions as an acetylcholinesterase (AChE) inhibitor. It exhibits therapeutic potential for the treatment of herpes infections, cancer, and inflammatory conditions, making it a promising candidate for further pharmacological research. -
MAPK inhibitor
MAPK-IN-1 (Compound 2) is an inhibitor of the MAPK signaling pathway with demonstrated neuroprotective and anti-neuroinflammatory properties. It also exhibits acetylcholinesterase (AChE) inhibitory activity, with an IC₅₀ of 23.84 μM, contributing to enhanced cholinergic signaling. These combined actions make MAPK-IN-1 a promising candidate for research in Alzheimer's disease and other neurodegenerative disorders, where modulation of MAPK signaling and cholinergic function are of therapeutic interest. -
NDs Inhibitor
NDs-IN-1 is a non-covalent multi-target inhibitor designed to inhibit the activities of key enzymes including human beta-secretase 1 (hBACE-1), human acetylcholinesterase (hAChE), and human monoamine oxidase B (hMAO-B). This compound is primarily utilized in research focused on neurodegenerative diseases, offering potential avenues for understanding disease mechanisms and developing therapeutic strategies. -
AChE Inhibitor
AChE-IN-105 is a potent mixed inhibitor of acetylcholinesterase (AChE) with an IC50 value of 5.02 μM. It exhibits significant antioxidant properties by scavenging reactive oxygen species (ROS) and mitigating hydrogen peroxide-induced activation of Caspase-3, while also downregulating the Nrf2-ARE pathway. In preclinical studies, AChE-IN-105 demonstrated the ability to prevent memory deficits in a zebrafish model of scopolamine-induced cognitive dysfunction. This compound is valuable for research focused on Alzheimer's disease and cognitive impairment mechanisms. -
AChE Inhibitor
SCR1693 is a selective, reversible, orally active noncompetitive inhibitor of acetylcholinesterase (AChE), with an IC50 value of 0.68 μM, and exhibits calcium channel blocking properties. This compound effectively reduces tau phosphorylation levels and inhibits the generation and release of amyloid-beta (Aβ). Additionally, SCR1693 has been shown to restore insulin signaling and improve cognitive deficits, making it a valuable tool for studying Alzheimer's disease, particularly in cases complicated by type 2 diabetes mellitus. -
AChE Inhibitor
MR2938 is a potent acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 of 5.04 μM. In addition to its enzymatic activity, MR2938 significantly reduces nitric oxide production, with an IC50 of 3.29 μM. This compound effectively mitigates neuroinflammation by inhibiting the MAPK/JNK and NF-κB signaling pathways. MR2938 is applicable for research focused on Alzheimer's disease and related neurodegenerative conditions. -
AChE Inhibitor/Metal Ion Chelating Agent
AD-35 is a potent acetylcholinesterase (AChE) inhibitor and a metal ion chelating agent, designed for research in Alzheimer’s disease. It demonstrates AChE and butyrylcholinesterase (BuChE) inhibition with IC50 values of 793 nM and 31,428 nM, respectively. AD-35 effectively chelates copper (Cu²⁺) and iron (Fe³⁺) ions, while exhibiting limited interaction with zinc (Zn²⁺). Additionally, AD-35 can inhibit amyloid-beta (Aβ) aggregation, destabilize pre-formed Aβ aggregates, and inhibit Aβ-induced ERK phosphorylation. Its ability to reduce neuroinflammation in rat models of Alzheimer's and improve cognitive performance underscores its potential in therapeutic research. -
ERK/BACE1/PSEN1 Inhibitor
L-Citronellol ((S)-3,7-Dimethyloct-6-en-1-ol) is an ERK/BACE1/PSEN1 inhibitor known for its anti-allergic and neuroprotective properties. This compound effectively inhibits mast cell activation and subsequent release of inflammatory mediators by targeting the ERK pathway. Additionally, L-Citronellol decreases the activity of BACE1, PSEN1, and acetylcholinesterase (AChE), while reducing TNF-α expression and lipid peroxidation, indicating its potential utility in multi-target approaches for Alzheimer's disease research. -
AChE Inhibitor
Linarin is a selective inhibitor of acetylcholinesterase (AChE), demonstrating oral bioavailability. This compound exhibits a range of biological activities, including anti-inflammatory, antioxidant, sedative, and antibacterial properties. Linarin is valuable for research in neurological disorders, osteoporosis, and cancer, providing insights into potential therapeutic applications across these areas. -
BChE/HDAC6 Inhibitor
BChE/HDAC6-IN-2 is a potent dual inhibitor targeting both butyrylcholinesterase (BChE) and histone deacetylase 6 (HDAC6), demonstrating IC50 values of 1.8 nM and 71.0 nM, respectively. This compound exhibits significant neuroprotective properties and scavenges reactive oxygen species (ROS), alongside effectively chelating metal ions such as Fe2+ and Cu2+. Furthermore, BChE/HDAC6-IN-2 inhibits tau phosphorylation and presents moderate immunomodulatory effects, making it a valuable reagent for research into neurodegenerative diseases and related pathways. -
AChE/HDAC Inhibitor
AChE/HDAC-IN-1 is a potent dual inhibitor of acetylcholinesterase (AChE) and histone deacetylases (HDAC) with IC50 values of 0.12 nM and 0.23 nM, respectively. This compound also demonstrates antioxidant activity and metal chelating properties, making it a valuable tool in understanding neurodegenerative processes. AChE/HDAC-IN-1 is suitable for research applications related to Alzheimer's disease and other conditions associated with cholinergic dysfunction and epigenetic modifications. -
HDAC6 Inhibitor
HDAC6-IN-5 is a potent inhibitor of histone deacetylase 6 (HDAC6), demonstrating an IC50 of 0.025 μM. This compound effectively inhibits the self-aggregation of amyloid-beta 1-42 and acetylcholinesterase (AChE), with IC50 values of 3.0 μM and 0.72 μM, respectively. HDAC6-IN-5 has been shown to promote neurite outgrowth while exhibiting minimal neurotoxicity, making it a valuable tool for research in neurodegenerative disease and neuronal regeneration studies. -
HDAC6 Inhibitor
HDAC6-IN-6 is a potent inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 of 0.025 μM. This compound is capable of crossing the blood-brain barrier and demonstrates strong inhibitory activity against amyloid-beta peptide (Aβ1-42) self-aggregation and acetylcholinesterase (AChE) with IC50 values of 3.0 μM and 0.72 μM, respectively. Additionally, HDAC6-IN-6 enhances neurite outgrowth while maintaining a favorable safety profile, making it a valuable tool for research in neurodegenerative diseases and related fields. -
BChE/HDAC6 Inhibitor
BChE/HDAC6-IN-1 is a selective dual inhibitor targeting both butyrylcholinesterase (BChE) and histone deacetylase 6 (HDAC6), with IC50 values of 4 nM and 8.9 nM, respectively. This compound demonstrates significant potential in ameliorating cognitive impairment in an Aβ1–42-induced mouse model, making it a valuable tool in Alzheimer's disease research. Its ability to modulate both cholinergic and epigenetic pathways positions BChE/HDAC6-IN-1 as a promising candidate for studies focused on neurodegenerative disorders. -
Anti-inflammatory agent, AChE Inhibitor, P450 Inhibitor, Neuroprotective agents
Acetylshikonin is a potent anti-inflammatory agent that also functions as an inhibitor of acetylcholinesterase (AChE) and non-selective cytochrome P450 enzymes. With an IC50 of 34.6 μM for AChE, Acetylshikonin exhibits neuroprotective properties and can induce apoptosis and autophagy in cancer cells. Its ability to regulate blood glucose and liver fat metabolism makes it valuable in research related to diabetes, diabetic nephropathy, obesity, and nonalcoholic fatty liver disease. -
Cholinesterase (ChE) Inhibitor
Scopoletin is a cholinesterase inhibitor that primarily targets acetylcholinesterase (AChE). It possesses notable biological activity in preventing the breakdown of acetylcholine, thereby enhancing cholinergic transmission. Scopoletin is commonly used in research focused on neurodegenerative diseases, cognitive disorders, and potential therapeutic interventions involving cholinergic systems. -
AChE/SERT Inhibitor
BGC-201259 is a potent and orally active inhibitor of acetylcholinesterase (AChE) and serotonin transporter (SERT), with IC50 values of 101 nM and 42 nM, respectively. Additionally, it inhibits the 5-HT receptor with an IC50 of 90 nM. BGC-201259 exhibits varying activity against several targets, including the norepinephrine transporter (IC50 = 7.7 μM), L-type calcium channel (IC50 = 3.6 μM), σ receptor (IC50 = 2 μM), and sodium channel (IC50 = 5.1 μM). This compound shows promise in research related to Alzheimer's disease by potentially enhancing cognitive and emotional functions through its dual-targeting mechanism. -
AChE Inhibitor
Flucopride is an AChE inhibitor with an IC50 of 24 nM, demonstrating significant potency in acetylcholinesterase modulation. Additionally, it acts as a partial agonist at the 5-HT4 receptor with a binding affinity (Ki) of 9.6 nM. Flucopride facilitates non-amyloidogenic processing of amyloid precursor protein (APP) in COS-7 cells expressing the human 5-HT4 receptor, with an EC50 of 23.0 nM. Its properties suggest effective gastrointestinal tract penetration and the capability to cross the blood-brain barrier, as indicated by PAMPA assay results, making it relevant for neuropharmacology research. -
AChE Inhibitor
Kokusaginine is a furoquinoline alkaloid that acts as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 28.2 μM. This compound has demonstrated anti-proliferative and apoptotic effects in MCF-7/ADR cancer cell lines, making it a valuable reagent for research in neurobiology and cancer biology. Its ability to modulate cholinergic signaling and induce cell death highlights its potential for further investigation in therapeutic applications. -
CDK2/9 Inhibitor
ZLMT-12 is a potent CDK2/9 inhibitor, demonstrating IC50 values of 0.002 μM and 0.011 μM against CDK9 and CDK2, respectively. This compound is derived from tacrine and exhibits weak inhibition of acetylcholinesterase (IC50 = 19.023 μM) and butyrylcholinesterase (IC50 = 2.768 μM). ZLMT-12 is characterized by low toxicity and notable antiproliferative activity, effectively inducing apoptosis and facilitating cell cycle arrest in the S and G2/M phases. This compound serves as a valuable tool for research in cell cycle regulation and therapeutic development in cancer biology. -
ChA Inhibitor
α-NETA is a potent noncompetitive inhibitor of choline acetyltransferase (ChA), exhibiting an IC50 value of 9 μM. Additionally, it displays strong antagonistic activity against aldehyde dehydrogenase 1A1 (ALDH1A1) with an IC50 of 0.04 µM and also targets chemokine-like receptor-1 (CMKLR1). While it shows some inhibitory effects on cholinesterase (ChE) and acetylcholinesterase (AChE) with higher IC50 values, α-NETA is notable for its anti-cancer properties, making it a valuable tool for research in cancer biology and neuropharmacology. -
Cholinesterase (ChE) Inhibitor
β-NETA is a potent noncompetitive inhibitor of cholinesterase (ChE) and choline acetyltransferase (ChA), with IC50 values of 40 μM and 76 μM, respectively. Additionally, it exhibits weak inhibitory effects on acetylcholinesterase (AChE), with an IC50 value of 1 mM. This compound is relevant for research in neurobiology and studies focused on cholinergic signaling pathways and associated disorders. -
BChE Inhibitor
Gypsogenin is a selective mixed-type inhibitor of butyrylcholinesterase (BChE) with a Ki of 19.99 μM. It demonstrates significant cytotoxicity against multiple human cancer cell lines by inducing cell cycle arrest and initiating apoptosis. Additionally, Gypsogenin exhibits antibacterial properties against species such as Bacillus subtilis and Bacillus thuringiensis, positioning it as a crucial scaffold for developing novel anticancer agents. This compound is extensively utilized in research focusing on Alzheimer's disease and various cancers, including colon cancer, melanoma, and leukemia.
